Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

109.50 -1.57 (-1.41%)
Streaming Delayed Price Updated: 11:06 AM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,520,021
Open 110.13
Bid (Size) 109.49 (2)
Ask (Size) 109.52 (1)
Prev. Close 111.07
Today's Range 109.08 - 110.71
52wk Range 83.05 - 119.65
Shares Outstanding 2,531,374,696
Dividend Yield 2.37%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Want to Grow Richer? These Stocks Have Doubled in the Past 5 Years
These two pharmaceutical companies have created value for shareholders. 
Via The Motley Fool
Arcus Biosciences Soars On Roche's 'Meaningful' Results In A New Cancer Drug Class
Roche tested its treatment in patients with liver cancer and found "meaningful" results. 
Via Investor's Business Daily

Performance

YTD
-1.48%
-1.48%
1 Month
-5.88%
-5.88%
3 Month
+0.13%
+0.13%
6 Month
+0.97%
+0.97%
1 Year
+18.98%
+18.98%

More News

Read More
Why PDS Biotech Shares Are Jumping Today
Via Benzinga
Amazon's Prime Video Trolls Netflix's Password Crackdown, Tesla Data Leak Exposes Safety Nightmare, Elon Musk's Brain Chip Company Gets FDA Nod For Human Trial: Top Stories For Today
Via Benzinga
AstraZeneca/Merck's Cancer Drug Combo Shows Positive Results In Endometrial Cancer
Via Benzinga
Here's How Much You Would Have Made Owning Merck & Co Stock In The Last 5 Years
Via Benzinga
Looking At Merck & Co's Recent Unusual Options Activity
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
Via Benzinga
After Back To Back Failure For Keytruda Plus Lenvima, Merck Touts Durable Clinical Benefit For The Combo In Advanced Kidney Cancer
Via Benzinga
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
7 Stocks That Could Be the Next $2 Trillion-Dollar Companies
Via InvestorPlace
Merck Announces Third-Quarter 2023 Dividend
From Merck & Co., Inc.
Via Business Wire
Doximity is an Overlooked Medical Ecosystem AI Play
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Undervalued Pharma Stocks to Buy for High Total Returns
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Via MarketBeat
Topics Economy
Exposures Economy
Shhh! 3 Healthcare Stocks Quietly Hitting 52-Week Highs
Via InvestorPlace
Immutep Shares Spike As Cancer Tratement Shows Favorable Results In Phase 2 Trial
Via Benzinga
FTC Files Lawsuit To Stop Amgen Buying Horizon Therapeutics, Sending Shockwaves Through Biopharma M&A
Via Benzinga
Merck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting
From Merck & Co., Inc.
Via Business Wire
3 Penny Stocks That Could Make You a Millionaire by 2025
Via InvestorPlace
The 3 Best MedTech Stocks to Watch in May 2023
Via InvestorPlace
Is ChatGPT A Better Financial Advisor? We're Going To Find Out
Via Benzinga
Can You Still Buy the Dow Jones' Best-Performing April Stocks?
Via The Motley Fool
Pharma ETFs Gain Post Q1 Earnings
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.